Spotlight Innovation Subsidiary Memcine Pharmaceuticals Signs Lease for Laboratory Facilities at The BioVentures Center Located at The University of Iowa Research Park

WEST DES MOINES, IA--(Marketwired - Sep 10, 2015) - Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Memcine Pharmaceuticals has signed a lease for use of a wet laboratory at the Coralville, IA-based BioVentures Center located at The University of Iowa Research Park. The lease provides for access to additional shared bioscience and translational medical research facilities.

Tony Vanden Bush, PhD, co-founder, co-inventor, Director and Chief Scientific Officer of Memcine Pharmaceuticals, said, "The BioVentures Center is an outstanding biomedical research resource and we are excited to be continuing our R&D activities there. We will initially utilize our new space to advance our stoichiometric research as it pertains to antibody and drug coupling."

Cris Grunewald, President and CEO of Spotlight Innovation, said, "The BioVentures Center provides new technology ventures such as Memcine Pharmaceuticals with a nurturing environment that is best-in-class. We are gratified to be working with the people and facilities of the BioVentures Center as we move Memcine Pharmaceuticals into the next phase of its development."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies, acquires and incubates companies that have unique intellectual property (IP) in the medical sector. The Company has relationships with the nation's leading academic and institutional IP developers, and locates promising IP technologies with potential for market share capture. With strong support, development, resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at www.spotlightinnovation.com.

About Memcine Pharmaceuticals, Inc.

Memcine Pharmaceuticals, Inc. is an early-stage biotech company focused on enhancing vaccine efficacy to improve human and animal health globally. Memcine's Immunoplex™ technology platform uses the body's naturally occurring targeting system to deliver vaccine components. The current portfolio of potential infectious disease vaccine targets includes influenza, HepB, and Ebola. Memcine Pharmaceuticals has also conducted pre-clinical experiments in a mouse model of breast cancer, where the vaccine technology showed considerable promise as a therapeutic treatment. Additional information available at www.memcine.com.

Forward Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.